The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is a global conference highlighting the latest advances in cancer research and care. GRASP provides a unique opportunity for advocates and clinical researchers to join the conversation through Poster Walkthroughs.

Register Below

This ASCO26 Poster Walkthrough group will explore key findings from the following posters:

Poster #1036: Prognostic impact of PIK3CA amplifications and co-occurring mutations detected through circulating tumor DNA (ctDNA) in metastatic breast cancer (MBC).

Poster #TPS1148: ReDiscover-2, a phase 3 study of zovegalisib (zovega, RLY-2608) + fulvestrant (fulv) versus capivasertib (capi) + fulv as treatment for locally advanced or metastatic PIK3CA-mutant HR+/ HER2- breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor.

Track: Breast Cancer—Metastatic  |  Subtrack: Biologic Correlates, Hormone Receptor-Positive (HR+) |  Keywords: PI3K, ctDNA, Co-mutations, Trial in progress